A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for Non-Hodgkin's lymphoma

Journal of Nuclear Medicine

Volumn 40, Issue 12, 1999, Pages 2014-2020

  O'Donnell, Robert T ^a,b   DeNardo, Gerald L ^a   Kukis, David L ^a   Lamborn, Kathleen R ^a   Shen, Sui ^a   Yuan, Aina ^a   Goldstein, Desiree S ^a   Carr, Catherine E ^a   Mirick, Gary R ^a   DeNardo, Sally J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Molecular Cancer Institute   (United States)

Author keywords

67Cu; Antibody; Immunotherapy; Lymphoma; Radiotherapy

Indexed keywords

COPPER 67; MONOCLONAL ANTIBODY LYM 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION HAZARD; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA;

BONE MARROW; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE;

EID: 0033375231     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Devesa SS, Fears T. Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res. 1992;52(suppl):5432s-5440s.
2. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol. 1998;16:3246-3256.
3. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974-1981.
4. 131I-B1 (anti-CD20) antibody therapy with aulologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346:336-340.
5. Rose LM, Gunasekera AH, DeNardo SJ, DeNardo GL, Meares CF. Lymphomaselective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother. 1996;43:26-30.
6. Hu E, Epstein AL, Naeve GS, et al. A phase I a clinical trial of Lym-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies. Hematol Oncol. 1989;7:155-166.
7. DeNardo SJ, DeNardo GL, O'Grady LF, et al. Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody. Antibody Immunoconj Radiopharm. 1988;1:17-33
8. 131I-Lym-1 antibody. Cancer Biother Radiopharm. 1998;13:239-254.
9. DeNardo GL, Lamhorn KR, Goldstein DS, Kroger LA, DeNardo SJ. Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Cancer. 1997;80 (suppl):2706-2711.
10. Lamborn KR, DeNardo GL, DeNardo SJ, et al. Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies. Clin Cancer Res. 1997;3:1253-1260.
11. DeNardo GL, O'Donnell RT, Rose LM, et al. Milestones in the development of Lym-1 radioimmunotherapy. Hybridoma. 1999;18:1-11.
12. Moi MK, Meares CF, McCall MJ, Cole WC, DeNardo SJ. Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. Anal Biochem. 1985;148:249-253.
13. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J Nucl Med. 1999;40:302-310.
14. 67Cu-2IT-BAT-Lym-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. Anticancer Res. 1998;18:2779-2788.
15. Wessels BW, Rogtis RD. Radionuclide selection and model adsorbed dose calculations for radiolabeled tumor associated antibodies. Medl Phys. 1984;11:638-645.
16. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage - The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer. 1982;49:2112-2135.
17. Wurflein D, Dechant M, Stockmeyer B, et al. Evaluating antibodies for their capacity Io induce cell-mediated lysis of malignant B cells. Cancer Res. 1998;58:3051-3058.
18. Kukis DL, DeNardo GL, DeNardo SJ, et al. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res. 1995;55:878-884.
19. Kukis DL, Diril H, Greiner DP, et al. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer. 1994;73(suppl):779-786.
20. 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with Burkitt's lymphoma (Raji). Clin Cancer Res. 1997;3:71-79.
21. DeNardo GL, Mirick GR, Kroger LA, O'Donnell RT, Meares CF, DeNardo SJ. Antibody responses to macrocycles in lymphoma. J Nucl Med. 1996;37:451-456.
22. Shen S, DeNardo GL, DeNardo SJ, et al. Dosimetric evaluation of Cu-64 in Cu-67-2IT-BAT-Lym-1 for radioimmunotherapy. J Nucl Med. 1996;37:146-150.
23. Coffey JL, Watson EE. Calculating dose from remaining body activity: a comparison of two methods. Med Phys. 1979;6:307-308.
24. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457-470.
25. Goldenberg DM, Horowitz JA, Sharkey RM, et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol. 1991;9:548-564.
26. Czuczman MS, Straus DJ, Divgi CR, et al. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J Clin Oncol. 1993;11:2021-2029.
27. Connett JM, Guo LW, Anderson CJ, et al. In vivo toxicity and long term radioimmunotherapy studies of Cu-64 and Cu-67 anti-colon carcinoma monoclonal antibody (MAb)-1A3 in the GW39-hamster model [abstrat]. J Nucl Med. 1995;36(suppl):92P.
28. DeNardo GL, DeNardo SJ. Perspectives on the future of radioimmunodiagnosis and radioimmunotherapy of cancer. In: Burchiel SW, Rhodes BA, eds. Radioimmunoimaging and Radioimmunotherapy. New York, NY: Elsevier Science Publishing; 1983:41-62.
29. 67Cu-labeled intact and fragmented anti-colon carcinoma monoclonal antibody MAb35. Cancer Res. 1993;53:5727-5733.
30. 131-labeled forms of monoclonal antibodies SEN7 and SWA20 directed against small cell lung cancer. Int J Cancer. 1994;8(suppl):43-48.
31. Sharkey RM, Motta-Hennessy C, Pawlyk D, Siegel JA, Goldenberg DM. Biodistribution and radiation dose estimates for yttrium-and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res. 1990;50:2330-2336.
32. DeNardo GL, DeNardo SJ, Miyao NP, et al. Non-dehalogenation mechanisms for excretion of radioiodine after administration of labeled antibodies. Int J Biol Markers. 1988;3:1-9.
33. Luza SC, Speisky HC. Liver copper storage and transport during development: implications for cytotoxicily. Am J Clin Nutr. 1996;63(suppl):812S-820S.
34. DeNardo GL, DeNardo SJ, Meares CF, et al. Pharmacokinetics of copper-67 conjugated Lym-1, a potential therapeutic radioimmunoconjugate, in mice and patients with lymphoma. Antibody Immunoconj Radiopharm. 1991;4:777-785.
35. Wessels BW, Vessella RL, Palme DF, Berkopec JM, Smith GK, Bradley EW. Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts. Int J Radiat Oncol Biol Phys. 1989;17:1257-1263.
36. 131I-Lym-1. Cancer Res. 1990;50(suppl):1014-1016.
37. Schlom J, Molinolo A, Simpson JF, et al. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst. 1990;82: 763-771.
38. DeNardo GL, Kukis DL, Shen S, DeNardo DA, Meares CF, DeNardo SJ. Copper-67 versus iodine-131 labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. Clin Cancer Res. 1999;5:533-541.
39. Delaloye AB, Delaloye B, Buchegger F, et al. Comparison of copper-67-and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors. J Nucl Med. 1997;38:847-853.